EXPEDITE: A 16-Week, Multicenter, Open-label Study of Remodulin Induction Followed by Orenitram Optimization in Subjects With Pulmonary Arterial Hypertension is a PHASE4 clinical asset sponsored by United Therapeutics in Pulmonary Arterial Hypertension. SEO and diligence focus: Intravenous/Subcutaneous Treprostinil; Oral Treprostinil, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.